The Value of Continuous (1 to 10 Years) Long-Term Anticoagulant Therapy

Article1 December 1957THE VALUE OF CONTINUOUS (1 TO 10 YEARS) LONG-TERM ANTICOAGULANT THERAPYBENJAMIN MANCHESTER, F.A.C.P.BENJAMIN MANCHESTER, F.A.C.P.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-47-6-1202 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptExperience in the last decade has established the therapeutic efficacy of anticoagulants. The successful prevention of thrombo-embolic complications, as well as the reduced mortality in myocardial infarction, has led to the continuation of antithrombotic therapy following recovery from an acute attack. The fear of recurrence, with increased mortality and disability, haunts the individual. The continuation of therapy proved effective in the acute phase, gives the patient reassurance and optimism. Prolonged anticoagulation therapy offers a physiologic approach toward prevention of subsequent myocardial infarction.This report presents the experience of continuous long-term anticoagulant therapy observed from one to 10 years in 712...Bibliography1. NicholFassett ESDW: An attempt to forestall acute coronary thrombosis; preliminary note on the continuous use of Dicumarol, South. M. J. 40: 631, 1947. CrossrefMedlineGoogle Scholar2. TullochWright JIS: Long-term anticoagulant therapy, further experiences, Circulation 9: 823, 1954. CrossrefMedlineGoogle Scholar3. SuzmanRuskinGoldburg MMHDB: Evaluation of the effect of continuous long-term anticoagulant therapy on the prognosis of myocardial infarction, Circulation 12: 338, 1955. CrossrefMedlineGoogle Scholar4. KeyesDrakeSmith JWEHFJ: Survival rates after acute myocardial infarction with long-term anticoagulant therapy, Circulation 14: 254, 1956. CrossrefMedlineGoogle Scholar5. Suzman MM: An evaluation of long-term anticoagulant therapy, Post-Grad. M. J. 32: 178, 1956. CrossrefMedlineGoogle Scholar6. ManchesterRabkin BB: The control of Dicumarol therapy in myocardial infarction by a simple blood prothrombin test, Circulation 10: 691, 1954. CrossrefMedlineGoogle Scholar7. Levine SA: Clinical heart disease, 4th Ed., 1952, W. B. Saunders Company, Philadelphia, p. 116. Google Scholar8. BlandWhite EFPD: Coronary thrombosis (with myocardial infarction) ten years later, J. A. M. A. 117: 1171, 1941. CrossrefGoogle Scholar9. GilbertFennNalefski NCGKLA: The role of coronary vasodilating drugs in coronary occlusion, J. Lab. and Clin. Med. 34: 797, 1949. MedlineGoogle Scholar10. SmithSchelling FJV: A clinical comparison of laboratory methods used in controlling anticoagulant therapy. Thrombosis and embolism, Proceedings of the 1st International Conference, 1954, Benno Schwabe & Co., Basel, p. 815. Google Scholar11. WareStragnell AGR: Anticoagulant therapy: elimination of some commonly occurring pitfalls, Ann. Int. Med. 46: 450, 1957. LinkGoogle Scholar12. OvermanStahmannLink RSMAKP: Studies on the hemorrhagic sweet clover disease. VIII. The effect of 2-methyl-1,4-naphthoquinone and 1-ascorbic acid upon the action of 3,3′methylenebis (4-hydroxy-coumarin) on the prothrombin time of rabbits, J. Biol. Chem. 145: 155, 1942. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Washington, D. C.*Presented at the Thirty-eighth Annual Session of The American College of Physicians, Boston, Massachusetts, April 8, 1957.From the Department of Medicine, The George Washington University School of Medicine, Washington, D. C.Requests for reprints should be addressed to Benjamin Manchester, M.D., Assistant Clinical Professor of Medicine, The George Washington University School of Medicine, Washington, D. C. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byClinical application of decision analysis: A detailed illustrationAnticoagulation Therapy for Coronary Heart DiseaseTherapeutic Decision Making: A Cost-Benefit AnalysisANTICOAGULANT TREATMENT OF ACUTE CORONARY THROMBOSISPathogenesis of Coronary Disease: With Comments on the Effect of Diet and DicumarolCurrent Myths and Realities in Anticoagulant Therapy for Coronary Heart DiseaseContinuous Anticoagulant Therapy Following Myocardial InfarctionProblems in the management of long-term anticoagulant therapy in coronary heart diseaseAn overview of anticoagulant therapy for coronary artery diseaseThe Use of Anticoagulants in Coronary Heart DiseaseAnticoagulant control in acute myocardial infarctionModern Treatment of Coronary Occlusion and InsufficiencyLONG-TERM ANTICOAGULANT CONTROL IN A RURAL AREAProblems Associated with Long-Term Anticoagulant TherapyThe Risk of Interrupting Long-Term Anticoagulant TreatmentPrevention of degenerative disease: A controlled study of anticoagulant prophylaxisLong-term anticoagulant therapy in an outpatient department. Techniques and complicationsTHROMBOTESTTRIAL OF A NON-SPECIFIC ANTI-CATARRH VACCINERecurrent myocardial infarction after cessation of anticoagulant therapyThe management of the patient after recovery from myocardial infarctionEXPERIENCES WITH LONG-TERM ANTICOAGULANT TREATMENTAnticoagulantien und HerzinfarktAcute myocardial infarction in a city hospitalCORONARY-ARTERY DISEASELONG-TERM ANTICOAGULANT THERAPY FOR CORONARY-ARTERY DISEASELONG-TERM ANTICOAGULANT TREATMENT FOR CORONARY-ARTERY DISEASECHLOROTHIAZIDE AND HYPOTENSIVE ACTION OF MECAMYLAMINELong-term Anticoagulant Treatment for Coronary-artery Disease 1 December 1957Volume 47, Issue 6Page: 1202-1209KeywordsAnticoagulant therapyAnticoagulantsDisabilitiesFearHemorrhageMortalityMyocardial infarctionRisk management ePublished: 1 December 2008 Issue Published: 1 December 1957 PDF downloadLoading ...